PL1753398T3

Controlled release matrix pharmaceutical dosage formulation

Abstract

This record has no abstract on file.

PL1753398T3, drawing sheet 1 — Sheet 1 of 7

Term

Term ended

Projected expiry passed 8 June 2025, 1.3 years ago.

7 sheets

Sheet 1
Sheet 2
Sheet 3
Sheet 4
Sheet 5
Sheet 6
Sheet 7

17 members in 9 offices

This recordMember, by publication datePriority claim

Priority claims10

Priority claims
Document	Office	Kind	Date
57893004	United States of America	P	2004-06-10
57893004	United States of America	P	2004-06-10
05759882	European Patent Office (EPO)	A	2005-06-08
2005020203	United States of America	W	2005-06-08
2005020203	United States of America	W	2005-06-08
057598823	–	–	–
578930P	–	–	–
EP20050759882	–	–	–
US20040578930P	–	–	–
WO2005US20203	–	–	–

Members17

Family members, oldest first
Document	Office	Kind
CA2569968A1	Canada	A1	2005-12-29
WO2005123045A2	World Intellectual Property Organization (WIPO)	A2	2005-12-29
WO2005123045A3	World Intellectual Property Organization (WIPO)	A3	2006-03-02
EP1753398A2	European Patent Office (EPO)	A2	2007-02-21
CN1988884A	China	A	2007-06-27
US2007212416A1	United States of America	A1	2007-09-13
JP2008502727A	Japan	A	2008-01-31
EP1753398A4	European Patent Office (EPO)	A4	2008-09-17
US2010255090A1	United States of America	A1	2010-10-07
CN1988884B	China	B	2013-01-02
JP2013216711A	Japan	A	2013-10-24
CA2569968C	Canada	C	2014-08-19
US9687451B2	United States of America	B2	2017-06-27
EP1753398B1	European Patent Office (EPO)	B1	2018-09-19
TR201819108T4	Türkiye	T4	2019-01-21
ES2702608T3	Spain	T3	2019-03-04
PL1753398T3This record	Poland	T3	2019-04-30